

Q1 2017 Financial Results

as of March **31, 2017**

Conference Call
May 4, 2017

SAFE HARBOR STATEMENT

Forward-looking statements involve risks.

This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this.

This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected.

It is not planned to update these forward-looking statements.

1. **Overview of the first three months of 2017**
2. Financials
3. Outlook & Focus in 2017
4. Q&A

HIGHLIGHTS Q1 2017

- Sales growth organically and with major clients in instrumentation
 - Sales total: +58.6%
 - Sales organically: +21.1%
- Financial guidance confirmed
- Highly promising contract negotiations including cross business unit opportunities
- Number of employees > 1,000
- Dividend proposal at € 0.77 per share (previous year: € 0.75)

1. Overview of the first three months of 2017
- 2. Financials**
3. Outlook & Focus in 2017
4. Q&A

FINANCIALS AT A GLANCE

Key figures after the first three months


| (in € million) | Mar 31, 2017 | Mar 31, 2016 | Change |
|-------------------------------------|--------------|--------------|----------------|
| Sales | 49.510 | 31.218 | +58.6% |
| EBITDA ¹ | 8.812 | 5.703 | +54.5% |
| EBITDA margin (%) ¹ | 17.8 | 18.3 | -50 bps |
| EBIT ² | 6.870 | 4.530 | +51.7% |
| EBIT margin (%) ² | 13.9 | 14.5 | -60 bps |
| Cons. net income ² | 5.369 | 3.424 | +56.8 |
| Earnings per share (€) ² | 0.45 | 0.29 | +55.2 |

¹ 2017 figure adjusted to exclude expenses resulting from transaction activities and related reorganization expenses

² 2017 figure additionally adjusted to exclude purchase price allocation-related amortization, financing expenses and tax expenses in connection with the acquisitions of the Diatron Group and STRATEC Consumables

SALES

3-Months Sales compared to Annual Sales




Q1|2017 Sales

- +58.6% to € 49.5 million
- Organic growth +21.1%
- Contribution of Diatron and STRATEC Consumables
- High volume of development activities

EBIT & EBIT MARGIN

As of March 31



EBIT margin affected by


- Product mix
- Diluted margins from new subsidiaries
- Hiring of staff in connection with numerous product developments

ADJUSTMENTS


| in € thousand | 01.01. - 31.03.2017 |
|--|---------------------|
| EBITDA | 8.461 |
| Adjustments | |
| Expenses due to company acquisitions | 270 |
| Reorganization expenses | 80 |
| Adjusted EBITDA | 8.812 |
| Depreciation and Amortization | -3.778 |
| Adjustments | |
| PPA Depreciation and Amortization | 1.836 |
| Adjusted EBIT | 6.870 |
| Net financial expenses | -275 |
| Current tax expenses | -1.252 |
| Deferred tax income | 264 |
| Adjustierungen | |
| Financing expenses due to company acquisitions | 220 |
| Current tax expenses | -157 |
| Deferred tax expenses | -301 |
| Adjusted consolidated net income | 5.369 |

EARNINGS AFTER THREE MONTHS

Key earnings figures as of March 31



Earnings per share as of March 31



- Q1 tax rate at 22.4% (previous year: 22.5%)
- Dividend proposal per share at € 0.77 (previous year : € 0.75)


1. Overview of the first three months of 2017
2. Financials
- 3. Outlook & Focus in 2017**
4. Q&A

FINANCIAL GUIDANCE

- Sales guidance for 2017: € 205 million to € 220 million
- Organic double digit top line growth in 2017
- Profitability in 2017 on a broadly stable level
- Guidance to be updated with H1 results in July 2017

FOCUS IN 2017 AND BEYOND

- Improve profitability across business (benefits of scale driven by top-line growth)
- Further realize synergies through development activities across STRATEC businesses
- Expand leading market role
- Facilitate process of instrument/consumables integration for partners
- Achieve milestones & market launches
- Execute important development and supply agreements



1. Overview of the first three months of 2017
2. Financials
3. Outlook & Focus in 2017
4. **Q&A**

QUESTIONS & ANSWERS



STRATEC Biomedical AG

Gewerbestr. 37
75217 Birkenfeld
Germany

Tel: +49 7082 7916-0
Fax: +49 7082 7916-999
www.stratec.com

Marcus Wolfinger
Chairman, Board of Management
m.wolfinger@stratec.com

TICKER

| | |
|------------|--------------|
| Symbol: | SBS.DE |
| Bloomberg: | SBS:GR |
| Reuters: | SBSG.DE |
| ISIN: | DE000STRA555 |
| WKN: | STRA55 |

THANK **YOU**
FOR **YOUR**
ATTENTION!